C Rad AB OMXSTO:CRAD_B:
Q1 ORDER INTAKE INCREASES 19% TO 115 MSEK
Q1 REVENUE DECREASES 12% TO 105 MSEK
Q1 EBIT EXCLUDING ONE-OFF COSTS AMOUNTS TO 22 MSEK, MARGIN 21%
C Rad Q1 Adjusted EBIT SEK 22 Mln
Watch C-Rad's latest callC-Rad (Stockholm:CRAD B) Q4 2025 Earnings Call · Replay · Feb 12Read the transcript of C-Rad (Stockholm:CRAD B) Q4 2025 Earnings CallEarlier from C-Rad
- C-RAD publishes its annual report for 2025
- CRAD_B: Service growth and recurring revenue offset lower product sales, supporting margin stability
- Invitation to presentation of C-RAD’s year-end report and report for the fourth quarter 2025
- C-RAD Appoints Tomas Blomquist As CEO
- CRAD_B: Q3 saw 12% revenue growth, 19% EBIT margin, and strong Services, with EMEA leading gains
Later from C-Rad
- C-RAD marks its new chapter at ESTRO 2026 with clinician-driven SGRT advances
- C-RAD and SeeTreat partner to deliver personalised radiotherapy for every patient
Follow C-Rad into a list and get an email when it puts out news.
Follow C-Rad